EA201070497A1 - Промежуточные продукты мгс - Google Patents

Промежуточные продукты мгс

Info

Publication number
EA201070497A1
EA201070497A1 EA201070497A EA201070497A EA201070497A1 EA 201070497 A1 EA201070497 A1 EA 201070497A1 EA 201070497 A EA201070497 A EA 201070497A EA 201070497 A EA201070497 A EA 201070497A EA 201070497 A1 EA201070497 A1 EA 201070497A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mgs
intermediate products
compounds
secretase activity
formula
Prior art date
Application number
EA201070497A
Other languages
English (en)
Inventor
Чих Юнг Хо
Original Assignee
Янссен Фармацевтика, Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика, Н.В. filed Critical Янссен Фармацевтика, Н.В.
Publication of EA201070497A1 publication Critical patent/EA201070497A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/31—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals

Abstract

Настоящее изобретение относится к использованию соединений с общей формулой I, включающей группы Rи R, природа которых объясняется в спецификации. Указанные соединения формулы I используются для синтеза ряда модуляторов γ-секретазной активности, в свою очередь, использующихся для лечения заболеваний, связанных с активностью γ-секретазы, включая болезнь Альцгеймера.
EA201070497A 2007-10-19 2008-10-17 Промежуточные продукты мгс EA201070497A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98125707P 2007-10-19 2007-10-19
PCT/US2008/080250 WO2009052341A1 (en) 2007-10-19 2008-10-17 Gsm intermediates

Publications (1)

Publication Number Publication Date
EA201070497A1 true EA201070497A1 (ru) 2010-12-30

Family

ID=40092042

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070497A EA201070497A1 (ru) 2007-10-19 2008-10-17 Промежуточные продукты мгс

Country Status (16)

Country Link
US (1) US20090306392A1 (ru)
EP (1) EP2209764A1 (ru)
JP (1) JP2011500720A (ru)
KR (1) KR20100081350A (ru)
CN (1) CN101903334A (ru)
AU (1) AU2008312362A1 (ru)
BR (1) BRPI0817789A2 (ru)
CA (1) CA2702911A1 (ru)
CO (1) CO6270355A2 (ru)
CR (1) CR11449A (ru)
EA (1) EA201070497A1 (ru)
IL (1) IL205040A0 (ru)
MX (1) MX2010004311A (ru)
NI (1) NI201000067A (ru)
WO (1) WO2009052341A1 (ru)
ZA (1) ZA201003521B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2814636C1 (ru) * 2020-09-11 2024-03-04 Бейджинг Хунхуэй Медитек Ко., Лтд Способ получения водорастворимых производных магнолола и производных хонокиола и их интермедиатов, и родственных моногидрокси-защищенных интермедиатов

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008312371B2 (en) * 2007-10-19 2013-06-20 Janssen Pharmaceutica, N.V. Amine linked modulators of gamma-secretase
WO2009052334A1 (en) * 2007-10-19 2009-04-23 Janssen Pharmaceutica, N.V. Carbon linked modulators of y-secretase
US8252935B2 (en) * 2007-10-19 2012-08-28 Janssen Pharmaceutica N.V. Piperidinyl and piperazinyl modulators of γ-secretase
CN105646452B (zh) * 2015-12-24 2018-05-01 北京康立生医药技术开发有限公司 一种蛋白激酶抑制剂的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
EP1650183A1 (en) * 2004-10-21 2006-04-26 Cellzome Ag (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy
PL1849762T3 (pl) * 2006-04-21 2009-12-31 Cellzome Ltd Podstawione kwasy bifenylo-karboksylowe i ich pochodne
DK1847524T3 (da) * 2006-04-21 2010-01-11 Cellzome Ltd Terphenylderivater til behandling af Alzheimers sygdom

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2814636C1 (ru) * 2020-09-11 2024-03-04 Бейджинг Хунхуэй Медитек Ко., Лтд Способ получения водорастворимых производных магнолола и производных хонокиола и их интермедиатов, и родственных моногидрокси-защищенных интермедиатов

Also Published As

Publication number Publication date
AU2008312362A1 (en) 2009-04-23
IL205040A0 (en) 2010-11-30
AU2008312362A2 (en) 2010-07-08
WO2009052341A1 (en) 2009-04-23
MX2010004311A (es) 2010-05-03
CN101903334A (zh) 2010-12-01
EP2209764A1 (en) 2010-07-28
KR20100081350A (ko) 2010-07-14
US20090306392A1 (en) 2009-12-10
BRPI0817789A2 (pt) 2015-03-24
CO6270355A2 (es) 2011-04-20
NI201000067A (es) 2010-09-13
JP2011500720A (ja) 2011-01-06
ZA201003521B (en) 2011-08-31
CA2702911A1 (en) 2009-04-23
CR11449A (es) 2011-01-14

Similar Documents

Publication Publication Date Title
CY1112429T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
BRPI0818581A2 (pt) Carboxamidas n-fenil-bipirrolidina substituídas e uso terapêutico das mesmas
EA201001647A1 (ru) Производные бензофурана, бензотиофена, бензотиазола в качестве fxr модуляторов
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
DK2212282T3 (da) Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf
CY1112391T1 (el) Υποκατεστημενες ν-φαινυλ-διπυρρολιδινη ουριες και θεραπευτικες χρησεις αυτων
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
ATE554076T1 (de) Sulfoximinsubstituierte chinazolinderivate als immunmodulatoren, ihre herstellung und ihre verwendung als medikamente
TW200716152A (en) Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture
CR11447A (es) Moduladores de piperidinil y piperazinil de y secretasa
EA200700707A1 (ru) Производные 2-ациламинотиазола
EA201070497A1 (ru) Промежуточные продукты мгс
EA201070496A1 (ru) УГЛЕРОД-СВЯЗАННЫЕ МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ
ATE392471T1 (de) Behandlung neurodegenerativer krankheiten durch verwendung von scd4-inhibitoren
MX2009013482A (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas.
EA201070494A1 (ru) МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ С АМИДНЫМИ СВЯЗЯМИ
WO2010011626A3 (en) Pyridinyl modulators of ϒ-secretase
EA201070498A1 (ru) МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ С АМИДНЫМИ СВЯЗЯМИ
EA201070478A1 (ru) Дифенилкарбоновые кислоты и их производные
DOP2004000982A (es) Compuestos para el tratamiento de trastornos neurodegenerativos